Hrain Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2015-07-20
- Employees
- 101
- Market Cap
- -
- Website
- http://www.dashengbio.com
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Phase 1
- Conditions
- POMES SyndromeRelapsed and Refractory POMES Syndrome
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03879382
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Phase 1
- Conditions
- CD19-positiveAcute Lymphoblastic Leukemia
- Interventions
- Drug: Human CD19 targeted T Cells Injection
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03798509
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Phase 1
- Conditions
- Follicular LymphomaCD19-positiveDiffuse Large B-cell Lymphoma
- Interventions
- Drug: Human CD19 targeted T Cells Injection
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03720457
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath